Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026

Same author

Identification and quantification of Hypocretin-1/Orexin-A 1-14 and 1-16 fragments in immunopurified cerebrospinal fluid using LC-MS: Comparison with radioimmunoassay (RIA) determinations.

Sleep medicine·2026

Same author

Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor-specific immunosignature.

Nature communications·2026

Same author

Current State and Needs of Clinical Laboratories in Latin America: A Cross-Country Assessment.

The journal of applied laboratory medicine·2026

Same author

An automated plasma-based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Biomarkers.

Bethany Schuder¹, Daniel Figdore¹, Joshua A Bornhorst¹

¹Mayo Clinic, Rochester, MN, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association

|December 24, 2025

Summary

This summary is machine-generated.

Fasting status impacts Alzheimer's disease blood biomarker concentrations, with significant differences observed for p-tau217 and NfL. Further research is needed to assess the clinical implications of these findings for Alzheimer's disease diagnosis.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

Area of Science:

Biochemistry
Neuroscience
Clinical Diagnostics

Background:

Alzheimer's disease (AD) blood biomarkers (BBMs) are crucial for clinical trials and practice.
Standardized protocols are needed to ensure reliable interpretation of BBMs.
Inconsistent findings exist regarding the effect of fasting on AD BBM concentrations.

Purpose of the Study:

To evaluate plasma concentrations of key AD biomarkers under fasting and non-fasting conditions.
To assess the influence of pre-analytical factors, specifically fasting, on biomarker measurements.
To compare fasting versus non-fasting sample collection for Alzheimer's disease blood biomarkers.

Main Methods:

Collected EDTA-plasma from 14 healthy donors (>55 years old) two weeks apart.
Samples were collected under standardized fasting (≥12 hours) and non-fasting conditions.
Measured plasma concentrations of amyloid-beta (Aβ) 42, Aβ40, phosphorylated Tau (p-tau) 181, p-tau217, and neurofilament light chain (NfL) using the Fujirebio Lumipulse G1200 analyzer.

Main Results:

Moderate to strong correlations were observed between fasting and non-fasting measurements for all tested biomarkers.
Statistically significant differences (p ≤ 0.05) were found for p-tau217, NfL, p-tau217/Aβ42, Aβ42/Aβ40, and Aβ42.
Average percent differences between conditions were notable for p-tau217 (27%) and p-tau217/Aβ42 (25%).

Conclusions:

Fasting status can lead to statistically significant differences in certain Alzheimer's disease blood biomarker concentrations.
Observed differences in biomarkers like p-tau217 and NfL warrant further investigation.
Additional studies are necessary to determine the clinical impact of these fasting-related variations on biomarker interpretation in individuals with amyloid pathology.